New combo therapy targets rare, aggressive kidney tumors
Disease control
Recruiting now
This phase 2 trial is testing two drugs—pembrolizumab (Keytruda) and enfortumab vedotin (Padcev)—in people with rare kidney cancers called collecting duct carcinoma and renal medullary carcinoma. About 23 patients with advanced or metastatic disease will receive the combination f…
Phase: PHASE2 • Sponsor: Giuseppe Procopio • Aim: Disease control
Last updated Jun 26, 2026 15:17 UTC